Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 May;65(5 Pt 2):64R-70R.
doi: 10.1203/PDR.0b013e3181a0977e.

Resistance to antimalarial drugs: molecular, pharmacologic, and clinical considerations

Mark A Travassos  1 , Miriam K Laufer
Affiliations
Review

Resistance to antimalarial drugs: molecular, pharmacologic, and clinical considerations

Mark A Travassos et al. Pediatr Res. 2009 May.

Abstract

One of the greatest obstacles to the control of malaria has been the spread of resistance to drugs used on a large scale. This review provides an update of the current understanding of the molecular basis for antimalarial drug resistance. Parasite intrinsic resistance is just one component that determines the in vivo efficacy of a drug. Human immune responses and pharmacologic properties play important roles in determining the clinical outcome of treatment. The emergence and spread of resistance also results from an interplay of these factors. Current efforts to characterize and deter resistance to new combination therapy are also discussed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic depiction of the clinical outcomes of drug efficacy studies when taking into account parasite, pharmacokinetic and host factors.
See this image and copyright information in PMC

References

    1. World Health Organization 2008 World Malaria Report 2008 Geneva WHO2. Trape JF, Legros F, Ndiaye P, Konate L, Bah IB, Diallo S, Verdier F, Hatin I, Le Bras J. Chloroquine-resistant Plasmodium falciparum malaria in Senegal. Trans R Soc Trop Med Hyg. 1989;83:761. - PubMed
    1. Trape JF, Legros F, Ndiaye P, Konate L, Bah IB, Diallo S, Verdier F, Hatin I, Le Bras J. Chloroquine-resistant Plasmodium falciparum malaria in Senegal. Trans R Soc Trop Med Hyg. 1989;A1:A2. - PubMed
    1. Zucker JR, Ruebush TK, Obonyo C, Otieno J, Campbell CC. The mortality consequences of the continued use of chloroquine in Africa: experience in Siaya, western Kenya. Am J Trop Med Hyg. 2003;68:386–390. - PubMed
    1. Sibley CH, Hyde JE, Sims PF, Plowe CV, Kublin JG, Mberu EK, Cowman AF, Winstanley PA, Watkins WM, Nzila AM. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol. 2001;17:582–588. - PubMed
    1. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect Dis. 2002;2:209–218. - PubMed

Publication types

MeSH terms